On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Thériault, Brigitte L ^a   Shepherd, Trevor G ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; MESOTHELIN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P53; ROSIGLITAZONE; STAT3 PROTEIN; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER STEM CELL; CANCER SUSCEPTIBILITY; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; EPITHELIAL OVARIAN CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE SRC; OVARY CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; UTERINE TUBE;

EID: 79959406708     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-10     Document Type: Review

References (13)

1. The preclinical natural history of serous ovarian cancer: defining the target for early deteciton. POPC Brown, PLoS Medicine 2009 6
2. Mutation of FOXL2 in granulosa-cell tumors of the ovary. SP Shah M Kobel J Senz RD Morin BA Clarke KC Wiegand G Leung A Zayed E Mehl SE Kalloger,, et al. N Engl J Med 2009 360 2719 2729 10.1056/NEJMoa0902542 19516027
3. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. M Kobel D Huntsman CB Gilks, Expert Rev Mol Med 2008 10 22 18671886
4. Cancer stem cells in solid tumors: an overview. CA O'Brien A Kreso JE Dick, Semin Radiat Oncol 2009 19 71 77 10.1016/j.semradonc.2008.11.001 19249644
5. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. K Levanon C Crum R Drapkin, J Clin Oncol 2008 26 5284 5293 10.1200/JCO.2008.18.1107 18854563
6. The distal fallopian tube: a new model for pelvic serous carcinogenesis. CP Crum R Drapkin A Miron TA Ince M Muto DW Kindelberger Y Lee, Curr Opin Obstet Gynecol 2007 19 3 9 10.1097/GCO.0b013e328011a21f 17218844 (Pubitemid 46095865)
7. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. JW Carlson A Miron EA Jarboe MM Parast MS Hirsch Y Lee MG Muto D Kindelberger CP Crum, J Clin Oncol 2008 26 4160 4165 10.1200/JCO.2008.16.4814 18757330
8. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. H Farmer N McCabe CJ Lord AN Tutt DA Johnson TB Richardson M Santarosa KJ Dillon I Hickson C Knights NM Martin SP Jackson GC Smith A Ashworth, Nature 2005 434 917 921 10.1038/nature03445 15829967 (Pubitemid 40559006)
9. Making the best of PARP inhibitors in ovarian cancer. S Banerjee SB Kaye A Ashworth, Nat Rev Clin Oncol 7 508 519
10. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink P Mortimer H Swaisland A Lau MJ O'Connor A Ashworth J Carmichael SB Kaye JH Schellens JS de Bono, N Engl J Med 2009 361 123 134 10.1056/NEJMoa0900212 19553641
11. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. AM Mendes-Pereira SA Martin R Brough A McCarthy JR Taylor JS Kim T Waldman CJ Lord A Ashworth, EMBO Mol Med 2009 1 315 322 10.1002/emmm.200900041 20049735
12. Understanding the Warburg effect: the metabolic requirements of cell proliferation. MG Vander Heiden LC Cantley CB Thompson, Science 2009 324 1029 1033 10.1126/science.1160809 19460998
13. The potential of PARP inhibitors in genetic breast and ovarian cancers. Y Drew H Calvert, Ann N Y Acad Sci 2008 1138 136 145 10.1196/annals.1414.020 18837894